Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

171.94 +6.56 (+3.97%)

Streaming Delayed Price Updated: 3:38 PM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact ↗

May 01, 2025

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Via Benzinga

Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets

May 01, 2025

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was...

Via StockStory

Topics Artificial Intelligence

Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar ↗

May 01, 2025

The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.

Via Investor's Business Daily

Topics Earnings

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Biogen Earnings: What To Look For From BIIB

April 30, 2025

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence World Trade

14 Analysts Have This To Say About Biogen ↗

April 22, 2025

Via Benzinga

How Is The Market Feeling About Biogen? ↗

March 07, 2025

Via Benzinga

1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore

April 24, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion ↗

April 16, 2025

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer's treatment.

Via Benzinga

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

April 15, 2025

From Biogen Inc.

Via GlobeNewswire

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks. ↗

April 10, 2025

From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care.

Via Investor's Business Daily

Topics Government

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

April 07, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United...

Via StockStory

Topics Artificial Intelligence

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

What 14 Analyst Ratings Have To Say About Biogen ↗

April 04, 2025

Via Benzinga

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

April 02, 2025

From Biogen Inc.

Via GlobeNewswire

European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen ↗

March 28, 2025

Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases.

Via Benzinga

Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025 ↗

March 27, 2025

Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company.

Via The Motley Fool

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

March 24, 2025

From Biogen Inc.

Via GlobeNewswire

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

March 24, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst...

Via StockStory

Topics Artificial Intelligence

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

March 20, 2025

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy ↗

March 19, 2025

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.

Via Benzinga

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

March 11, 2025

From Biogen Inc.

Via GlobeNewswire

Indexes Swimming In Red Ink On Recession Fears ↗

March 10, 2025

Stocks are looking to extend last week's losses, as recession fears grip Wall Street.

Via Talk Markets

Topics Economy Stocks / Equities

Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding ↗

March 06, 2025

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025,...

Via Benzinga

Stocks Plummet As Trade Partners Retaliate Against Tariffs ↗

March 04, 2025

Stocks are free falling as President Donald Trump's tariffs against Mexico, Canada, and China take effect.

Via Talk Markets

Topics Government Stocks / Equities World Trade

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

March 03, 2025

Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now trades at $140.49. This was partly driven by its softer quarterly results and...

Via StockStory

Synchronicity: Denying The Unexplainable ↗

February 24, 2025

Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?

Via Talk Markets

Topics Stocks / Equities

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗

February 24, 2025

Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.